
drug:eloralinitide
Amylin, with and without GLP1: Eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
drug:eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
category:side-effects
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
category:news
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
drug:retatrutide
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
politics
We take a look at the various movements in GLP1 policy by the Trump administration, so far.
drug:wegovy
Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
drug:nimacimab
Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.
company:eli-lilly
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
company:pfizer
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
category:news
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!
politics
Trump administration revokes the planned Medicare Part D coverage for anti-obesity GLP1 drugs.